These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 29627234

  • 1. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
    Dabaghian M, Latifi AM, Tebianian M, NajmiNejad H, Ebrahimi SM.
    Vaccine; 2018 May 11; 36(20):2886-2895. PubMed ID: 29627234
    [Abstract] [Full Text] [Related]

  • 2. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Dabaghian M, Latifi AM, Tebianian M, Dabaghian F, Ebrahimi SM.
    Antiviral Res; 2015 Aug 11; 120():23-31. PubMed ID: 25989418
    [Abstract] [Full Text] [Related]

  • 3. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
    Dabaghian M, Latify AM, Tebianian M, Nili H, Ranjbar AR, Mirjalili A, Mohammadi M, Banihashemi R, Ebrahimi SM.
    Vet Microbiol; 2014 Nov 07; 174(1-2):116-26. PubMed ID: 25293397
    [Abstract] [Full Text] [Related]

  • 4. Conjugating influenza a (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration.
    Liu Q, Zheng X, Zhang C, Shao X, Zhang X, Zhang Q, Jiang X.
    J Med Virol; 2015 Nov 07; 87(11):1807-15. PubMed ID: 25959372
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge.
    Shokouhi H, Farahmand B, Ghaemi A, Mazaheri V, Fotouhi F.
    Virus Res; 2018 Jun 02; 251():40-46. PubMed ID: 29730305
    [Abstract] [Full Text] [Related]

  • 7. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.
    Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248
    [Abstract] [Full Text] [Related]

  • 8. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W.
    J Control Release; 2009 Dec 03; 140(2):126-33. PubMed ID: 19712713
    [Abstract] [Full Text] [Related]

  • 9. Nasal Administration of M2e/CpG-ODN Encapsulated in N-Trimethyl Chitosan (TMC) Significantly Increases Specific Immune Responses in a Mouse Model.
    Taghizadeh M, Dabaghian M.
    Arch Razi Inst; 2022 Dec 03; 77(6):2259-2268. PubMed ID: 37274902
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens.
    Elaish M, Kang KI, Xia M, Ali A, Shany SA, Wang L, Jiang X, Lee CW.
    Vaccine; 2015 Sep 11; 33(38):4901-9. PubMed ID: 26232342
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model.
    Sadati SF, Jamali A, Abdoli A, Abedi-Valugerdi M, Gholami S, Alipour S, Soleymani S, Kheiri MT, Atyabi F.
    Pathog Dis; 2018 Nov 01; 76(8):. PubMed ID: 30184220
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, Gorshkov AN, Kasyanenko MA, Ravin NV, Kiselev OI.
    Vaccine; 2015 Jun 26; 33(29):3398-406. PubMed ID: 25976545
    [Abstract] [Full Text] [Related]

  • 15. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
    Slütter B, Jiskoot W.
    J Control Release; 2010 Nov 20; 148(1):117-121. PubMed ID: 20600405
    [Abstract] [Full Text] [Related]

  • 16. Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46.
    Amirnasr M, Fallah Tafti T, Sankian M, Rezaei A, Tafaghodi M.
    Microb Pathog; 2016 Aug 20; 97():38-44. PubMed ID: 27235335
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X, Hu K, Shen M, Kong N, Fu C, Yan W, Wei A.
    J Virol Methods; 2016 Feb 20; 228():84-90. PubMed ID: 26615805
    [Abstract] [Full Text] [Related]

  • 20. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
    Zhang J, Fan HY, Zhang Z, Zhang J, Zhang J, Huang JN, Ye Y, Liao M.
    Vaccine; 2016 Jan 27; 34(5):622-629. PubMed ID: 26724200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.